Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yeo, Seung-Gu | - |
dc.contributor.author | Kim, Min-Jeong | - |
dc.date.accessioned | 2021-08-11T17:24:56Z | - |
dc.date.available | 2021-08-11T17:24:56Z | - |
dc.date.issued | 2016-08 | - |
dc.identifier.issn | 1792-0981 | - |
dc.identifier.issn | 1792-1015 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8906 | - |
dc.description.abstract | Stereotactic body radiation therapy (SBRT) can significantly improve the treatment outcomes of patients with inoperable stage I non-small-cell lung cancer. Similarly, a few case studies have reported the effectiveness of SBRT for stage I small-cell lung cancer (SCLC). However, no study has investigated the use of SBRT for extensive-stage SCLC (ES-SCLC). Compared with conventional RT, SBRT is able to deliver a higher radiation dose precisely and safely to small targets in short-duration treatments. The present study reports the outcome of a patient with ES-SCLC who responded favorably to initial chemotherapy and received SBRT for a residual mass in the peripheral lung. A 62-year-old female presented with pathologically determined SCLC at clinical stage T4N3M0-T4 as separate tumor nodules were present in different ipsilateral lobes. The patient received 6 cycles of standard chemotherapy with cisplatin and etoposide. The response of the patient to chemotherapy was evaluated using contrast-enhanced chest computed tomography and F-18-fluorodeoxyglucose positron emission tomography-computed tomography. The only suspected residual viable tumor was a 1.5-cm mass in the right upper lobe. Targeting this mass, intensity-modulated SBRT was performed with 48 Gy in 4 fractions and 6 MV photons. In addition, prophylactic cranial irradiation was conducted with 25 Gy in 10 fractions. The patient is alive with no evidence of disease 4 years after treatment. SBRT toxicity was limited to radiation pneumonitis or fibrosis without pulmonary symptoms. This case report suggests the efficacy of SBRT in select ES-SCLC patients with small residual lung disease following chemotherapy. | - |
dc.format.extent | 4 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Spandidos Publications | - |
dc.title | Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report | - |
dc.type | Article | - |
dc.publisher.location | 그리이스 | - |
dc.identifier.doi | 10.3892/etm.2016.3359 | - |
dc.identifier.scopusid | 2-s2.0-84974659959 | - |
dc.identifier.wosid | 000380278900103 | - |
dc.identifier.bibliographicCitation | Experimental and Therapeutic Medicine, v.12, no.2, pp 1185 - 1188 | - |
dc.citation.title | Experimental and Therapeutic Medicine | - |
dc.citation.volume | 12 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 1185 | - |
dc.citation.endPage | 1188 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | ELECTIVE NODAL IRRADIATION | - |
dc.subject.keywordPlus | THORACIC RADIOTHERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | stereotactic body radiotherapy | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | small-cell lung cancer | - |
dc.subject.keywordAuthor | extensive stage | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.